|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Travis WD, Brambilla E and Riely GJ: New
pathologic classification of lung cancer: Relevance for clinical
practice and clinical trials. J Clin Oncol. 31:992–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ma G, Cai H, Gao L, Wang M and Wang H:
sCLU regulates cisplatin chemosensitivity of lung cancer cells in
vivo. World J Surg Oncol. 13:802015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yuan JM, Li XD, Liu ZY, Hou GQ, Kang JH,
Huang DY and Du SX: Cisplatin induces apoptosis via upregulating
Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev.
12:3465–3469. 2011.PubMed/NCBI
|
|
5
|
Koberle B, Tomicic MT, Usanova S and Kaina
B: Cisplatin resistance: Preclinical findings and clinical
implications. Biochim Biophys Acta. 1806:172–182. 2010.PubMed/NCBI
|
|
6
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Law S and Wong J: The current management
of esophageal cancer. Adv Surg. 41:93–119. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Han Z, Truong QA, Park S and Breslow JL:
Two Hsp70 family members expressed in atherosclerotic lesions. Proc
Natl Acad Sci USA. 100:pp. 1256–1261. 2003; View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ren A, Yan G, You B and Sun J:
Down-regulation of mammalian sterile 20-like kinase 1 by heat shock
protein 70 mediates cisplatin resistance in prostate cancer cells.
Cancer Res. 68:2266–2274. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yoshidomi K, Murakami A, Yakabe K, Sueoka
K, Nawata S and Sugino N: Heat shock protein 70 is involved in
malignant behaviors and chemosensitivities to cisplatin in cervical
squamous cell carcinoma cells. J Obstet Gynaecol Res. 40:1188–1196.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Steagall RJ, Hua F, Thirunazukarasu M,
Zhan L, Li C, Maulik N and Han Z: Abstract 3600: HspA12B promotes
angiogenesis through suppressing AKAP12 and up-regulating VEGF
pathway. Circulation. 118 Suppl 18:S4492008.
|
|
13
|
Ma H, Lu T, Zhang X, Li C, Xiong J, Huang
L, Liu P, Li Y, Liu L and Ding Z: HSPA12B: A novel facilitator of
lung tumor growth. Oncotarget. 6:9924–9936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang B, Liu ZM, Hao FG and Wang M:
siRNA-directed clusterin silencing promotes cisplatin antitumor
activity in human non-small cell lung cancer xenografts in
immunodeficient mice. Eur Rev Med Pharmacol Sci. 18:1595–1601.
2014.PubMed/NCBI
|
|
15
|
Bayne K: Revised guide for the care and
use of laboratory animals available. American physiological
society. Physiologist. 39:199–208, 111. 1996.PubMed/NCBI
|
|
16
|
Siddik ZH: Cisplatin: Mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su J, Wu S, Tang W, Qian H, Zhou H and Guo
T: Reduced SLC27A2 induces cisplatin resistance in lung cancer stem
cells by negatively regulating Bmi1-ABCG2 signaling. Mol Carcinog.
55:1822–1832. 2016. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lippard SJ: Platinum, Gold, and Other
Metal Chemotherapeutic Agents. 209. American Chemical Society;
Washington, DC: 1983, doi: 10.1021/bk-1983-0209. View Article : Google Scholar
|
|
19
|
Azijli K, Weyhenmeyer B, Peters GJ, de
Jong S and Kruyt FA: Non-canonical kinase signaling by the death
ligand TRAIL in cancer cells: discord in the death receptor family.
Cell Death Differ. 20:858–868. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang M, Liu ZM, Li XC, Yao YT and Yin ZX:
Activation of ERK1/2 and Akt is associated with cisplatin
resistance in human lung cancer cells. J Chemother. 25:162–169.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang M, Huang J, Pan HZ and Jin J:
Triptolide overcomes dexamethasone resistance and enhanced
PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human
multiple myeloma cells. Int J Mol Med. 22:489–496. 2008.PubMed/NCBI
|
|
22
|
Catz SD and Johnson JL: Transcriptional
regulation of bcl-2 by nuclear factor kappa B and its significance
in prostate cancer. Oncogene. 20:7342–7351. 2001. View Article : Google Scholar : PubMed/NCBI
|
